GAMMA Investing’s Core Laboratories CLB Stock Holding History

GAMMA Investing’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$46.3K	Sell	4,773 -47	-1%	-$544	﹤0.01%	2419
2026 Q2	$56.2K	Sell	4,820 -1,521	-24%	-$21.7K	﹤0.01%	2225
2026 Q1	$106K	Buy	6,341 +1,184	+23%	+$21.2K	0.01%	1621
2025 Q4	$82.7K	Buy	5,157 +2,181	+73%	+$32.5K	﹤0.01%	1709
2025 Q3	$36.8K	Buy	2,976 +777	+35%	+$9.11K	﹤0.01%	2185
2025 Q2	$25.3K	Sell	2,199 -2,382	-52%	-$28.3K	﹤0.01%	2340
2025 Q1	$68.7K	Sell	4,581 -1,821	-28%	-$30.5K	0.01%	1554
2024 Q4	$111K	Buy	6,402 +517	+9%	+$9.98K	0.01%	1038
2024 Q3	$109K	Buy	5,885 +1,460	+33%	+$29.3K	0.01%	937
2024 Q2	$89.8K	Buy	4,425 +855	+24%	+$15.1K	0.01%	842
2024 Q1	$61K	Buy	3,570 +857	+32%	+$13.5K	0.01%	905
2023 Q4	$42.8K	Buy	+2,713	New	+$54.7K	0.01%	993

Other funds holding CLB

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

HCA

Harpswell Capital Advisors Yarmouth, Maine $152M AUM 8.39% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing's CLB Position: Q3 2026 in Review

GAMMA Investing reduced its Core Laboratories (CLB) stake by 0.98% in Q3 2026, selling an estimated $544 and leaving 4,773 shares worth $46.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2419.

GAMMA Investing first reported a position in CLB in Q4 2023 and has held it in 12 quarters since. The position peaked at $111K in Q4 2024. 4 funds tracked by Wall St. Rank hold CLB as of Q3 2026.

GAMMA Investing held 4,773 shares of Core Laboratories worth $46.3K as of Q3 2026.
GAMMA Investing sold 47 Core Laboratories shares in Q3 2026, an estimated $544.
Core Laboratories made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2419 holding.
GAMMA Investing first reported a position in Core Laboratories in Q4 2023 and has held it in 12 quarters since.
GAMMA Investing's Core Laboratories position peaked at $111K in Q4 2024.
4 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.